Angeion's defibrillator lead to undergo US trials:
This article was originally published in Clinica
Executive Summary
Angeion plans to begin a US multicentre clinical trial of its new AngeFix 4090 lead system for defibrillators. The lead helps pace, sense and defibrillate the heart using a helix-shaped active fixation tip which can be "screwed" into the heart tissue and which also reduces the risk of the lead becoming dislodged. The Minneapolis, Minnesota-based company recently CE-marked the device which will be marketed in Europe by ELA Medical, a subsidiary of French company Synthelabo.